About 500 units of antivenom will be produced in South Africa.
This is significant because the country records 4,000 snake bites per year, resulting in 900 hospitalisations, according to the National Health Laboratory Service (NHL).
Of these cases, only 3% require antivenon.
Production dipped in a year, to critically low levels, because the South African Vaccine Producers were unable to manufacture doses.
Production restarted in early September with about 435 units of polyvalent antivenom, to target multiple toxins.
The National Health Laboratory Service (NHLS), said in a statement, “the production of antivenom is a complex and time-intensive process that requires extensive in-process inspections to ensure the safety, quality and effectiveness of every vial produced.”